Bristol Prepares For Life After Pravachol: Support Will Continue Into 2005
Executive Summary
Bristol-Myers Squibb will continue to promote Pravachol over the near term despite declining sales for the statin as wholesalers prepare for generic competition in 2006
You may also be interested in...
Bristol Outsourcing Of Cefzil, Tequin To Ventiv May Be New Model For CSOs
Bristol Myers-Squibb's sales agreement with Ventiv for the promotion of the antibiotics Cefzil and Tequin may be a new model for using contract sales organizations in an environment of downsizing
Bristol Outsourcing Of Cefzil, Tequin To Ventiv May Be New Model For CSOs
Bristol Myers-Squibb's sales agreement with Ventiv for the promotion of the antibiotics Cefzil and Tequin may be a new model for using contract sales organizations in an environment of downsizing
Zocor, Zoloft And Pravachol Will Be Key Generic Switches For Medco In ’06
Medco sees a significant opportunity for growth in 2006 generic switches, Group President-National Accounts Timothy Wentworth says